Betrixaban: Safely Reducing Venous Thromboembolic Events with Extended Prophylaxis

被引:3
|
作者
Dobesh, Paul P. [1 ]
Trevarrow, Brian J. [2 ]
机构
[1] Univ Nebraska Med Ctr, Coll Pharm, Dept Pharm Practice, 986145 Nebraska Med Ctr, Omaha, NE 68198 USA
[2] Univ Nebraska Med Ctr, Coll Pharm, Dept Pharmaceut & Nutr Care, Omaha, NE USA
来源
AMERICAN JOURNAL OF MEDICINE | 2019年 / 132卷 / 03期
关键词
Anticoagulation; Betrixaban; Direct oral anticoagulant; Venous thromboembolism prophylaxis; HOSPITALIZED MEDICAL PATIENTS; DURATION; RISK; THROMBOPROPHYLAXIS; PREVENTION; ENOXAPARIN;
D O I
10.1016/j.amjmed.2018.08.024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although venous thromboembolism prophylaxis of acute medically ill patients is commonly employed, a percentage of high-risk patients still have venous thromboembolic events within 30 days of discharge. Research over the last several years has attempted to identify characteristics of these high-risk patients to facilitate provision of extended prophylaxis and venous thromboembolic event reduction; however, extended prophylaxis has been associated with a significant increase in the risk for major bleeding until recently. Betrixaban, a new oral direct Xa inhibitor with once-daily dosing and limited renal elimination, significantly reduces the risk of venous thromboembolism without increasing the risk for major bleeding. Consequently, betrixaban is the only anticoagulant approved by the Food and Drug Administration for preventing venous thromboembolism with extended prophylaxis in acute medically ill patients. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:307 / 311
页数:5
相关论文
共 50 条
  • [11] Mandatory DVT Prophylaxis Does Not Reduce Venous Thromboembolic Events in Cancer Patients
    Asaro, J.
    Groman, A.
    Aquino, A.
    Skitzki, J.
    Kane, J. M.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : S38 - S39
  • [12] Prophylaxis for Venous Thromboembolic Events in Elective Total Hip and Total Knee Arthroplasty
    Karasavvidis, Theofilos
    Bouris, Vasileios
    Xiang, William
    Tzavellas, Georgios
    Charisis, Nektarios
    Palaiodimos, Leonidas
    Kigka, Vassiliki
    Bourantas, Christos, V
    Gkiatas, Ioannis
    CURRENT PHARMACEUTICAL DESIGN, 2022, 28 (10) : 771 - 777
  • [13] Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice
    Kayla M. Miller
    Michael J. Brenner
    Drugs, 2019, 79 : 291 - 302
  • [14] Venous thromboembolic prophylaxis for hip fractures
    D. Marsland
    S. C. Mears
    S. L. Kates
    Osteoporosis International, 2010, 21 : 593 - 604
  • [15] Statins and Venous Thromboembolic Disease Prophylaxis
    Wang, Cindy
    Lerner, Robert G.
    Frishman, William H.
    CARDIOLOGY IN REVIEW, 2013, 21 (06) : 295 - 299
  • [16] Venous thromboembolic prophylaxis for hip fractures
    Marsland, D.
    Mears, S. C.
    Kates, S. L.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 : S593 - S604
  • [17] Reducing venous thromboembolic events associated with ovarian cancer: are we winning the battle?
    O'Gorman, C.
    Burke, N.
    Norris, L.
    Gleeson, N.
    Abu Saadeh, F.
    THROMBOSIS RESEARCH, 2015, 135 : S66 - S66
  • [18] Venous thromboembolic prophylaxis - The use of aspirin
    Snyder, Brenda K.
    ORTHOPAEDIC NURSING, 2008, 27 (04) : 225 - 230
  • [19] Venous thromboembolic events in tuberculosis
    Dabo, Hans
    Vaz, Manuel
    Teixeira, Nelson
    Gomes, Isabel
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [20] Venous thromboembolic disease - the challenge of prophylaxis
    Tsang, FJ
    Davies, AH
    PHLEBOLOGY, 2004, 19 (04) : 161 - 162